Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2e)-n-(4-(3-chloro-4-fluoroanilino)-7-(((3s)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide
2. Afatinib
3. Afatinib Maleate
4. Bibw 2992
5. Bibw 2992 Ma2
6. Bibw 2992ma2
7. Bibw-2992
8. Bibw-2992-ma2
9. Bibw-2992ma2
10. Bibw2992
11. Bibw2992 Ma2
12. Gilotrif
1. 850140-73-7
2. Afatinib (dimaleate)
3. Gilotrif
4. Afatinib Maleate
5. Bibw 2992ma2
6. Giotrif
7. Afatinib (bibw2992) Dimaleate
8. Afatinib Dimaleate [usan]
9. Bibw2992 Ma2
10. Afatinib Maleate (jan)
11. V1t5k7rz0b
12. Bibw-2992ma2
13. Bibw2992-ma2
14. Bibw-2992 Ma2
15. Bibw-2992-ma2
16. Chebi:76003
17. 850140-73-7 (dimaleate)
18. Bibw2992 Dimaleate
19. Afatinib Dimaleate (usan)
20. (s,e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide Dimaleate
21. Afatinib Maleate [jan]
22. Afatinib Impurity F
23. (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide Bis(hydrogen (2z)-but-2-enedioate)
24. (z)-but-2-enedioic Acid;(e)-n-[4-(3-chloro-4-fluoroanilino)-7-[(3s)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
25. Unii-v1t5k7rz0b
26. Mfcd25974239
27. Gilotrif (tn)
28. Giotrif (tn)
29. Bibw2993 Dimaleate
30. Amy499
31. Afatinib Dimaleate [mi]
32. Chembl2105712
33. Afatinib Dimaleate [vandf]
34. Dtxsid701027713
35. Afatinib Dimaleate [who-dd]
36. Hy-10261a
37. S7810
38. Akos025401819
39. Ccg-270401
40. Cs-1329
41. Afatinib Dimaleate [orange Book]
42. Ac-26080
43. As-56967
44. Ba162012
45. D09733
46. Q27145677
47. (2e)-n-(4-[(3-chloro-4-fluorophenyl)amino]-7-{[(3s)-tetrahydrofuran-3-yl]oxy}quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
48. (2e)-n-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3s)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide Dimaleate
49. (2e)-n-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3s)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Di[(2z)-but-2-enedioate]
50. (e)-4-dimethylamino-but-2-enoic Acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((s)-tetra-hydrofuran-3-yloxy)-quinazolin-6yl)-amide Dimaleate
51. 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2e)-, (2z)-2-butenedioate (1:2)
52. 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2e)-, (2z)-2-butenedioate (1:2)
53. 936631-70-8
Molecular Weight | 718.1 g/mol |
---|---|
Molecular Formula | C32H33ClFN5O11 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 12 |
Exact Mass | 717.1849127 g/mol |
Monoisotopic Mass | 717.1849127 g/mol |
Topological Polar Surface Area | 238 Ų |
Heavy Atom Count | 50 |
Formal Charge | 0 |
Complexity | 821 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Giotrif as monotherapy is indicated for the treatment of
- Epidermal Growth Factor Receptor (EGFR) TKI-nave adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);
- locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE13
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
51
PharmaCompass offers a list of Afatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Afatinib manufacturer or Afatinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Afatinib manufacturer or Afatinib supplier.
PharmaCompass also assists you with knowing the Afatinib API Price utilized in the formulation of products. Afatinib API Price is not always fixed or binding as the Afatinib Price is obtained through a variety of data sources. The Afatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A BIBW 2992 MA2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BIBW 2992 MA2, including repackagers and relabelers. The FDA regulates BIBW 2992 MA2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BIBW 2992 MA2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of BIBW 2992 MA2 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A BIBW 2992 MA2 supplier is an individual or a company that provides BIBW 2992 MA2 active pharmaceutical ingredient (API) or BIBW 2992 MA2 finished formulations upon request. The BIBW 2992 MA2 suppliers may include BIBW 2992 MA2 API manufacturers, exporters, distributors and traders.
click here to find a list of BIBW 2992 MA2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A BIBW 2992 MA2 DMF (Drug Master File) is a document detailing the whole manufacturing process of BIBW 2992 MA2 active pharmaceutical ingredient (API) in detail. Different forms of BIBW 2992 MA2 DMFs exist exist since differing nations have different regulations, such as BIBW 2992 MA2 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A BIBW 2992 MA2 DMF submitted to regulatory agencies in the US is known as a USDMF. BIBW 2992 MA2 USDMF includes data on BIBW 2992 MA2's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The BIBW 2992 MA2 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of BIBW 2992 MA2 suppliers with USDMF on PharmaCompass.
A BIBW 2992 MA2 written confirmation (BIBW 2992 MA2 WC) is an official document issued by a regulatory agency to a BIBW 2992 MA2 manufacturer, verifying that the manufacturing facility of a BIBW 2992 MA2 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting BIBW 2992 MA2 APIs or BIBW 2992 MA2 finished pharmaceutical products to another nation, regulatory agencies frequently require a BIBW 2992 MA2 WC (written confirmation) as part of the regulatory process.
click here to find a list of BIBW 2992 MA2 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing BIBW 2992 MA2 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for BIBW 2992 MA2 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture BIBW 2992 MA2 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain BIBW 2992 MA2 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a BIBW 2992 MA2 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of BIBW 2992 MA2 suppliers with NDC on PharmaCompass.
BIBW 2992 MA2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of BIBW 2992 MA2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right BIBW 2992 MA2 GMP manufacturer or BIBW 2992 MA2 GMP API supplier for your needs.
A BIBW 2992 MA2 CoA (Certificate of Analysis) is a formal document that attests to BIBW 2992 MA2's compliance with BIBW 2992 MA2 specifications and serves as a tool for batch-level quality control.
BIBW 2992 MA2 CoA mostly includes findings from lab analyses of a specific batch. For each BIBW 2992 MA2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
BIBW 2992 MA2 may be tested according to a variety of international standards, such as European Pharmacopoeia (BIBW 2992 MA2 EP), BIBW 2992 MA2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BIBW 2992 MA2 USP).